Results 61 to 70 of about 1,181 (123)

Intravitreal ranibizumab or conbercept for retinal arterial macroaneurysm: a case series

open access: yesBMC Ophthalmology, 2019
Background There is no consensus for the standard treatment of retinal arterial macroaneurysm (RAM). Intravitreal anti-vascular endothelium growth factor (anti-VEGF) is an alternative treatment option for RAM. The purpose of this study is to describe the
Zhongjing Lin   +4 more
doaj   +1 more source

Intravitreal Injection of Conbercept Combined with Dexamethasone for Macular Edema Following Central Retinal Vein Occlusion

open access: yesClinical Ophthalmology
Peipei Wu,1 Panpan Zhang,1 Jing Xu,1 Wenhui Ma,1 Longfei Li,2 Haifeng Xu1 1Department of Uveitis, Eye Institute of Shandong First Medical University, Qingdao Eye Hospital of Shandong First Medical University, Qingdao, People’s Republic of China; 2College
Wu P, Zhang P, Xu J, Ma W, Li L, Xu H
doaj  

Profile of conbercept in the treatment of neovascular age-related macular degeneration

open access: yesDrug Design, Development and Therapy, 2015
Xinmin Lu,1 Xiaodong Sun1–31Department of Ophthalmology, Shanghai First People’s Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai, People’s Republic of China; 2Eye Research Institute of Shanghai Jiao Tong University,
Lu XM, Sun XD
doaj  

Efficacy and Safety of Intravitreal Conbercept, Ranibizumab, and Triamcinolone on 23-Gauge Vitrectomy for Patients with Proliferative Diabetic Retinopathy

open access: yesJournal of Ophthalmology, 2018
Introduction. To compare the effect and safety of intravitreal conbercept (IVC), intravitreal ranibizumab (IVR), or intravitreal triamcinolone acetonide (IVTA) injection on 23-gauge (23-G) pars plana vitrectomy (PPV) for proliferative diabetic ...
Jinglin Cui   +8 more
doaj   +1 more source

Clinical effectiveness of ranibizumab and conbercept for neovascular age-related macular degeneration: a meta-analysis

open access: yesDrug Design, Development and Therapy, 2018
Luping Wang,1 Canwei Zhang,2 Rui Hua3 1Department of Ophthalmology, University of Bonn, Bonn, Germany; 2Department of Ophthalmology, Weifang Eye Hospital, Weifang, People’s Republic of China; 3Department of Ophthalmology, First Hospital of China ...
Wang LP, Zhang CW, Hua R
doaj  

Short-term efficacy of intravitreal conbercept in treatment-naive patients with polypoidal choroidal vasculopathy

open access: yesDrug Design, Development and Therapy, 2018
Yuting Peng, Xiongze Zhang, Miaoling Li, Bing Liu, Lan Mi, Chengguo Zuo, Feng Wen State Key Laboratory of Ophthalmology, Zhongshan Ophthalmic Center, Sun Yat-sen University, Guangzhou, China Introduction: To evaluate the functional and morphological ...
Peng Y   +6 more
doaj  

Issue Information

open access: yes
Clinical Case Reports, Volume 13, Issue 10, October 2025.
wiley   +1 more source

Two-year outcomes of intravitreal conbercept therapy for polypoidal choroidal vasculopathy

open access: yesBMC Ophthalmology
Background This study aims to evaluate the two-year outcomes of polypoidal choroidal vasculopathy (PCV) treated with conbercept and to investigate the predictive response factors.
Yang Liu   +4 more
doaj   +1 more source

Topical Ophthalmic Liposomes Dual-Modified with Penetratin and Hyaluronic Acid for the Noninvasive Treatment of Neovascular Age-Related Macular Degeneration

open access: yesInternational Journal of Nanomedicine
Chen Sun,1,* Shuyue Zhang,1,* Nan Xu,1,* Kun Liu,2 Fang Wei,2 Xiaoqian Zhang,1 Jigang Zhang,1 Shen Gao,3 Yuan Yu,4 Xueying Ding1 1Clinical Research Center, Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai,
Sun C   +9 more
doaj  

Home - About - Disclaimer - Privacy